Valeant And Gilead: Beaten Down Bargains Or Truly Terrible?

Valeant Pharmaceuticals (NYSE: VRX) and Gilead Sciences (NASDAQ: GILD) are in the bargain bin, but first quarter financial results show that sales continue to decline at both companies. Are these companies making enough progress to make them worth owning in portfolios?In this episode of the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell search Valeant Pharmaceuticals and Gilead Sciences first-quarter financials for clues to determine if now is a good time to buy.Thanks to Slack for supporting Motley Fool.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News